GlassScriptPhysician profile
James Collins
NPI 1811105331
$1,622.29
in general payments reported to CMS, 2019-2025
21 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $72.37 · 2021: $128 · 2022: $32.27 · 2023: $409 · 2024: $376 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $385.92 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Boston Scientific Corporation | $350.42 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $170.74 | 2023-2025 | Epidiolex |
| Sk Life Science, INC. | $121.70 | 2025 | Xcopri |
| Ucb, INC. | $91.87 | 2023-2024 | Briviact, Nayzilam |
| Ipsen Biopharmaceuticals, INC | $80.88 | 2022-2024 | Dysport |
| Supernus Pharmaceuticals, INC. | $52.78 | 2023-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $51.26 | 2022-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Catalyst Pharmaceuticals, INC. | $45.14 | 2024 | |
| Ascendis Pharma Endocrinology INC | $43.27 | 2024 | |
| Dexcom, INC. | $39.90 | 2025 | Dexcom G6 Transmitter |
| Corium, LLC | $30.19 | 2023 | Azstarys |
| Zogenix INC. | $23.87 | 2020 | |
| Upsher-Smith Laboratories LLC | $21.37 | 2025 | |
| Qol Medical, LLC | $18.12 | 2024 | Sucraid |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.69 | 2023 | Abilify Maintena, Rexulti |
| Neurelis, INC. | $17.38 | 2023 | Valtoco |
| Ns Pharma, INC. | $16.80 | 2023 | Viltepso |
| Novo Nordisk INC | $14.63 | 2025 | Ozempic, Rybelsus |
| Sarepta Therapeutics, INC. | $14.39 | 2023 | |
| Livanova USA, INC. | $13.97 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.